- Home
- TPCS vs IGC Comparison
TPCS vs IGC Comparison
Compare TPCS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPCS | IGC |
|---|---|---|
| Founded | 1956 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 28.5M |
| IPO Year | 2008 | 2005 |
Fundamental Metrics
Financial Performance| Metric | TPCS | IGC |
|---|---|---|
| Price | $3.67 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 58.8K | ★ 266.2K |
| Earning Date | 02-17-2026 | 06-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.20 | 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,031,000.00 | $1,271,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $2.08 | $0.24 |
| 52 Week High | $6.25 | $0.50 |
Technical Indicators
Market Signals| Indicator | TPCS | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 44.70 |
| Support Level | $3.14 | N/A |
| Resistance Level | $3.85 | $0.32 |
| Average True Range (ATR) | 0.23 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 48.21 | 12.18 |
Price Performance
Historical ComparisonAbout TPCS TechPrecision Corporation
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.